Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study Evaluating Navitoclax After Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

NCT05564650 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT05564650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05564650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study Evaluating Navitoclax After Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Lead sponsor
Thomas Jefferson University
Phase
Phase 1
Overall status
Completed
Start date
January 12, 2023
Completion date
May 8, 2026
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome, recurrent myelodysplastic syndrome, refractory myelodysplastic syndrome